Prism Medico and Pharmacy Limited Fundamental Analysis (BSE: PRISMMEDI.BO)
Prism Medico and Pharmacy Limited Fundamental Analysis (BSE: PRISMMEDI.BO)
Prism Medico and Pharmacy Limited (BSE: PRISMMEDI.BO) shows weak financial fundamentals with a PE ratio of -49.31, profit margin of -42.02%, and ROE of -2.61%. The company generates $0.0B in annual revenue with N/A year-over-year growth of N/A.
Key Strengths
Areas of Concern
The stock receives a Fundamental Health Score of -5.2/100 based on profitability, valuation, growth, and balance sheet metrics. The F grade reflects weak fundamentals and significant financial concerns.
Fundamental Health Score
We analyze PRISMMEDI.BO's fundamental strength across five key dimensions:
Efficiency Score
WeakPRISMMEDI.BO struggles to generate sufficient returns from assets.
Valuation Score
ExcellentPRISMMEDI.BO trades at attractive valuation levels.
Growth Score
ModeratePRISMMEDI.BO shows steady but slowing expansion.
Financial Health Score
ExcellentPRISMMEDI.BO maintains a strong and stable balance sheet.
Profitability Score
WeakPRISMMEDI.BO struggles to sustain strong margins.
Key Financial Metrics
Is PRISMMEDI.BO Expensive or Cheap?
P/E Ratio
PRISMMEDI.BO trades at -49.31 times earnings. This suggests potential undervaluation.
PEG Ratio
When adjusting for growth, PRISMMEDI.BO's PEG of 0.32 indicates potential undervaluation.
Price to Book
The market values Prism Medico and Pharmacy Limited at 2.81 times its book value. This may indicate undervaluation.
EV/EBITDA
Enterprise value stands at -64.08 times EBITDA. This is generally considered low.
How Well Does PRISMMEDI.BO Make Money?
Net Profit Margin
For every $100 in sales, Prism Medico and Pharmacy Limited keeps $-42.02 as profit after all expenses.
Operating Margin
Core operations generate -41.50 in profit for every $100 in revenue, before interest and taxes.
ROE
Management delivers $-2.61 in profit for every $100 of shareholder equity.
ROA
Prism Medico and Pharmacy Limited generates $-2.54 in profit for every $100 in assets, demonstrating efficient asset deployment.
Following the Money - Real Cash Generation
Operating Cash Flow
Prism Medico and Pharmacy Limited generates limited operating cash flow of $0.00, signaling weaker underlying cash strength.
Free Cash Flow
Prism Medico and Pharmacy Limited generates weak or negative free cash flow of $0.00, restricting financial flexibility.
FCF Per Share
Each share generates $0.00 in free cash annually.
FCF Yield
PRISMMEDI.BO converts 0.00% of its market value into free cash.
Financial Ratios Analysis
Valuation Ratios
P/E Ratio
Price to earnings ratio
-49.31
vs 25 benchmark
PEG Ratio
Price/earnings to growth ratio
0.32
vs 25 benchmark
P/B Ratio
Price to book value ratio
2.81
vs 25 benchmark
P/S Ratio
Price to sales ratio
19.04
vs 25 benchmark
Financial Health
Debt/Equity
Total debt to shareholders' equity
0.00
vs 25 benchmark
Current Ratio
Current assets to current liabilities
77.37
vs 25 benchmark
Efficiency Ratios
ROE
Return on equity percentage
-0.03
vs 25 benchmark
ROA
Return on assets percentage
-0.03
vs 25 benchmark
ROCE
Return on capital employed
-0.03
vs 25 benchmark
How PRISMMEDI.BO Stacks Against Its Sector Peers
| Metric | PRISMMEDI.BO Value | Sector Average | Performance |
|---|---|---|---|
| P/E Ratio | -49.31 | 21.07 | Better (Cheaper) |
| ROE | -2.61% | 647.00% | Weak |
| Net Margin | -42.02% | -1592.00% (disorted) | Weak |
| Debt/Equity | 0.00 | 0.90 | Strong (Low Leverage) |
| Current Ratio | 77.37 | 912.43 | Strong Liquidity |
| ROA | -2.54% | -579.00% (disorted) | Weak |
PRISMMEDI.BO outperforms its industry in 3 out of 6 key metrics, but lagging in ROE.
Historical Growth Performance
5-Year Growth Trajectory
This section reviews Prism Medico and Pharmacy Limited's 5-year compound annual growth rate (CAGR) and compares its performance against the typical investment style of its industry.
Revenue CAGR
N/A
Industry Style: Value, Dividend, Cyclical
EPS CAGR
N/A
Industry Style: Value, Dividend, Cyclical
FCF CAGR
N/A
Industry Style: Value, Dividend, Cyclical